Table 1 Pharmacokinetic parameters after intravenous or oral administration of T-13 and T-26 in rats.

From: T-13 and T-26, the novel taxanes with improved oral bioavailability in rats

Parameters

T-13

T-26

Intravenous (5 mg/kg)

Oral (60 mg/kg)

Intravenous (5 mg/kg)

Oral (60 mg/kg)

t1/2 (h)

3.21 ± 0.53

2.97 ± 0.55

10.21 ± 1.72

10.44 ± 1.14

Cmax (ng/mL)

7990.72 ± 3466.17

921.51 ± 560.87

11017.79 ± 2679.59

2121.12 ± 454.09

Tmax (h)

—

0.8 ± 0.2

—

3.0 ± 1.1

AUC0−t (ng·h/mL)

3310.69 ± 1333.34

4249.99 ± 2484.31

3439.76 ± 1479.88

25306.31 ± 6148.79

AUC0−∞ (ng·h/mL)

3318.42 ± 1333.11

4265.72 ± 2493.71

4054.33 ± 1860.39

32010.17 ± 8537.60

MRT0-∞ (h)

2.58 ± 0.87

4.33 ± 0.74

10.08 ± 2.60

15.19 ± 1.71

F (%)

10.71

65.79

  1. AUC0−t: area under the concentration-time curve from time 0 to 24 h; AUC0−∞: area under the concentration-time curve from time 0 to ∞; Cmax: peak concentration; Tmax: time to peak concentration; MRT: mean residence time; t1/2: half-life of the terminal phase.
  2. F: absolute oral bioavailability, F = (AUCp.o × Dosei.v)/(AUCi.v × Dosep.o) × 100%.
Back to article page